文献速递免疫规划卫生政策与健康促进慢病防控与筛查

安大略省老年人呼吸道合胞病毒病疫苗接种的影响与成本效果分析:加拿大免疫研究网络(CIRN)研究

Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
PubMed 文献 · Vaccine · 2024-02-16

该研究用离散事件模拟模型评估安大略省60岁及以上人群接种Arexvy或Abrysvo预防RSV下呼吸道疾病的健康获益与成本效果。以每QALY 5万加元支付意愿阈值,长期护理院居民接种覆盖率90%时,Arexvy在每剂价格不超过163加元时具有成本效果;扩展至社区老年人(覆盖率74%)时,每剂价格不超过139加元仍具成本效果。

要点

  • 长期护理院居民接种覆盖率90%时,Arexvy在每剂≤163加元下具成本效果,ICER为每QALY 49,984加元。
  • 扩展至社区老年人覆盖率74%时,Arexvy在每剂≤139加元下具成本效果,ICER为每QALY 49,698加元。
  • 与不接种相比,长期护理院接种使住院减少7.0%,扩展程序使RSV相关住院减少57.3%。

核心结论

  • 长期护理院居民接种RSV疫苗是否具成本效果取决于每剂价格;扩展至社区老年人可带来显著健康获益,避免大量直接医疗费用和生产力损失。

研究设计与样本

  • 采用离散事件模拟模型,参数基于加拿大安大略省60岁及以上成人RSV疾病负担(含门诊、住院和死亡),计算净货币效益和每剂价格范围,评估两个RSV季节内医疗保健和社会视角的成本效果。

主要发现

  • 长期护理院居民接种覆盖率90%时,Arexvy在每剂价格不超过163加元时从社会视角具成本效果,ICER为每QALY 49,984加元(95%CI:47,539至52,704),两年预算影响为每10万老年人463,468加元。
  • 与不接种相比,长期护理院接种估计使住院减少7.0%。
  • 与不接种相比,扩展程序使RSV相关住院减少57.3%。

关键数值与推荐

  • 支付意愿阈值为每QALY 5万加元。
  • 长期护理院居民接种覆盖率90%,Arexvy每剂价格≤163加元时具成本效果(社会视角)。
  • 社区老年人接种覆盖率74%,Arexvy每剂价格≤139加元时具成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two prefusion F protein-based vaccines, Arexvy and Abrysvo, have been approved by Health Canada for protecting older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease. We estimated the health benefits and cost-effectiveness of these vaccines under a publicly funded single-dose vaccination program in Ontario that targets residents of long-term care homes (LTCHs). Additionally, we evaluated an extended program that broadens vaccination to include community-dwelling older adults. METHODS: A discrete-event simulation model was parameterised with the burden of RSV disease including outpatient care, hospitalisation, and death among adults aged 60 years or older in Ontario, Canada. Accounting for direct and indirect costs (in 2023 Canadian dollars) associated with RSV-related outcomes, we calculated the net monetary benefit using quality-adjusted life-year (QALY) gained, and determined the range of price-per-dose (PPD) for vaccination programs to be cost-effective from both healthcare and societal perspectives over two RSV seasons. The incremental cost-effectiveness ratio (ICER) was calculated to estimate the additional costs required to gain one QALY. RESULTS: Using a willingness-to-pay of $50,000 per QALY gained, we found that vaccinating 90% of residents in LTCHs with Arexvy would be cost-effective from a societal perspective for a PPD up to $163, producing a mean ICER value of $49,984 (95% CI: $47,539 to $52,704) per QALY gained with a two-year budget impact of $463,468 per 100,000 older adults. The reduction of hospitalizations was estimated at 7.0% compared to the no-vaccination scenario. Extending the program to include community-dwelling older adults with a 74% coverage akin to influenza vaccination, Arexvy remains cost-effective for a PPD up to $139, with a mean ICER value of $49,698 (95% CI: 48,022 to 51,388) per QALY gained and a two-year budget impact of $8.63 million. Compared to the no-vaccination scenario, the extended program resulted in a 57.3% reduction in RSV-related hospitalisations. CONCLUSIONS: Vaccinating residents of LTCHs against RSV disease would be cost-effective depending on PPD; extending the program to community-dwelling older adults would provide substantial health benefits, averting significant direct healthcare costs and productivity losses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shoukat A, Bawden CE, Röst G, et al. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine. 2024. PMID: 38368226. doi:10.1016/j.vaccine.2024.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。